Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Author: ZHEJIANG WENDA PHARMACEUTICAL TECHNOLOGY CO., LTD.

Posted Date: